Compare ING Groep NV (ING) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Viatris Inc — how do they compare? ING Groep NV trades at $33.36 (market cap $93.76B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: ING Groep NV is far larger — about 4.7× Viatris Inc's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Viatris Inc for 57 Days on average.
| ING | VTRS | |
|---|---|---|
Market Cap | $93.76B | $20.03B |
Volume | 4,620,220 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $37.27 | $18.27 |
52-Week Low | $23.66 | $9.74 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $236.48B | $32.15B |
Dividend Yield | 3.95% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.92, down 2.81% today, with a bearish technical outlook despite recent earnings beats. The company shows strong profitability with 28.34% net income margin and 13.49% ROE, supported by management's raised ROE target above 16% for 2027. Recent news highlights strategic focus on organic growth and bolt-on acquisitions while maintaining capital discipline.
While analyst consensus remains strongly bullish with 65% buy ratings, negative cash flow trends and regulatory scrutiny in Australia present near-term risks. The stock's attractive valuation at 12.86 P/E offers potential upside if the company can execute on its growth strategy and improve cash generation.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
